MedPath

Post-Market Clinical Survey of Clareon® IOL AutonoMe™ in Japanese Subjects

Completed
Conditions
Cataract
Registration Number
NCT03824028
Lead Sponsor
Alcon Research
Brief Summary

This purpose of this survey study is to collect and describe clinical outcomes for the intraocular lens (IOL) delivery performance of Clareon® IOL AutonoMe™ when used in daily practice.

Detailed Description

This study will enroll subjects who underwent prior cataract surgery with phacoemulsification and were implanted with Clareon intraocular lenses (IOLs) using the Clareon® IOL AutonoMe™ automated preloaded delivery system. Subjects will be enrolled post-operatively and followed for one year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
384
Inclusion Criteria
  • Able to comprehend and willing to sign informed consent.
  • Prior diagnosis of age-related cataracts.
  • Prior cataract surgery with implantation of Clareon IOL in the capsular bag by AutonoMe™.
  • No ophthalmic disease which might affect visual acuity.
Exclusion Criteria
  • None.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Difference between target refraction and postoperative subjective refraction (spherical equivalent)Up to Year 1 postoperative

Visual acuity will be collected under well-lit conditions at a distance of five meters using a decimal visual acuity chart. Subjective refraction at best corrected distance vision will be recorded and compared with target refraction determined on day of surgery.

Best-corrected distance visual acuityUp to Year 1 postoperative

Visual acuity will be collected under well-lit conditions at a distance of five meters using a decimal visual acuity chart.

Intraocular lens (IOL) delivery performanceSurgery day (retrospective)

A questionnaire will be used to retrospectively evaluate the usability of AutonoME™. The investigator will respond to 8 questions pertaining to the IOL delivery performance using a 5-point scale where 1 = very good/strongly agree and 5 = very poor/strongly disagree.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Alcon Investigative Site

🇯🇵

Hashimoto, Wakayama, Japan

Alcon Investigative Site
🇯🇵Hashimoto, Wakayama, Japan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.